Scholarlink

Background <p>Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by postural instability, rigidity, bradykinesia, and resting tremors. Neuroinflammation has been implicated in PD pathogenesis, with inflammatory cytokines serving as potential biomarkers for disease progression and therapeutic monitoring. This study aimed to assess the effects of boswellic acids’ supplementation&#xa0;(the main active component of Strowell®) on motor and cognitive function in PD patients, as well as its impact on inflammatory biomarkers.</p> Methods <p>In a 6-month, randomized, double-blind, placebo-controlled clinical trial, 58 PD patients were assigned to receive either boswellic acids or a placebo. Clinical assessments included the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment (MoCA), with comparisons to baseline scores. Inflammatory biomarkers were measured at baseline and after 1 month.</p> Results <p>After 6 months, UPDRS scores remained stable in the boswellic acids group but significantly worsened in the placebo group (<i>p</i> = 0.0008). MoCA scores showed a slight but non-significant improvement in the treatment group, while no improvement was observed in the placebo group. In addition, 1 month of boswellic acids’ supplementation led to a significant reduction in plasma levels of pro-inflammatory cytokines, including IL-4, IL-1A, IL-12p70, INF-γ, IL-1β, TNF-α, IL-6, and PGE2.</p> Conclusion <p>The findings suggest that boswellic acids’ supplementation may help mitigate motor function decline in PD patients while exerting significant anti-inflammatory effects. These results support the potential role of boswellic acids as an adjunctive therapy for Parkinson’s disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Boswellic acids as an adjunct therapy in Parkinson’s disease: a double-blind clinical trial investigating on its effects on motor symptoms and inflammatory markers

  • 期刊论文

  • 发表日期：

    2025年10月2日

查看全文
  • Somayyeh Shateri,
  • Seyyed Hossein Khatami,
  • Sajad Ehtiati,
  • Mohammad Reza Talebzadeh,
  • Sadegh Nikakhtar,
  • Monir Hassani Parvar,
  • Seyedeh Ozra Hosseini,
  • Gholamali Shahidi,
  • Amir Hossein Habibi,
  • Farzaneh Salmani,
  • Fatemeh Namvarjah,
  • Ali Riazi,
  • Abbas Tafakhori,
  • Saeed Karima

摘要

Background

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by postural instability, rigidity, bradykinesia, and resting tremors. Neuroinflammation has been implicated in PD pathogenesis, with inflammatory cytokines serving as potential biomarkers for disease progression and therapeutic monitoring. This study aimed to assess the effects of boswellic acids’ supplementation (the main active component of Strowell®) on motor and cognitive function in PD patients, as well as its impact on inflammatory biomarkers.

Methods

In a 6-month, randomized, double-blind, placebo-controlled clinical trial, 58 PD patients were assigned to receive either boswellic acids or a placebo. Clinical assessments included the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Montreal Cognitive Assessment (MoCA), with comparisons to baseline scores. Inflammatory biomarkers were measured at baseline and after 1 month.

Results

After 6 months, UPDRS scores remained stable in the boswellic acids group but significantly worsened in the placebo group (p = 0.0008). MoCA scores showed a slight but non-significant improvement in the treatment group, while no improvement was observed in the placebo group. In addition, 1 month of boswellic acids’ supplementation led to a significant reduction in plasma levels of pro-inflammatory cytokines, including IL-4, IL-1A, IL-12p70, INF-γ, IL-1β, TNF-α, IL-6, and PGE2.

Conclusion

The findings suggest that boswellic acids’ supplementation may help mitigate motor function decline in PD patients while exerting significant anti-inflammatory effects. These results support the potential role of boswellic acids as an adjunctive therapy for Parkinson’s disease.